drugset / Trial / NCT05510427
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find the highest tolerable dose of infigratinib that can be given in combination with bevacizumab and atezolizumab to patients with advanced/metastatic CCA with a FGFR2 mutation.
Timeline
- Start
- 2023-08-07
- Primary completion
- 2023-08-07
- Completion
- 2023-08-07
Outcome
Outcome not reported
Stopped: “Per PI's request”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Infigratinib | Small molecule | — | Oral |